Zobrazeno 1 - 5
of 5
pro vyhledávání: '"A De Basagoiti Gorordo"'
Autor:
S Mendiola Garcia, LR López Giménez, B San Jose Ruiz, A Belaustegui Foronda, A De Basagoiti Gorordo, G Ros Bernaola
Publikováno v:
European Journal of Hospital Pharmacy. 23:A148.1-A148
Background Patients with chemosensitive neuroendocrine tumours are often treated with a capecitabine protocol (750 mg/m2/12 h day 1 to day 14) and temozolomide (200 mg/m2/24 h day 10 to day 14). A patient treated with this protocol in our centre pres
Autor:
M Castaño Lopez, A Belaustegui Foronda, G Ros Bernaola, B San Jose Ruiz, I Bilbao Meseguer, LR López Giménez, A Bustinza Txertudi, B Sordo Aisa, A De Basagoiti Gorordo, Z Baskaran Kaltzakorta
Publikováno v:
European Journal of Hospital Pharmacy. 22:A128.1-A128
Background Patients with tuberous sclerosis often develop facial angiofibromas that can be successfully treated with topical 1% sirolimus ointments. Nevertheless, this ointment’s greasy nature can produce acne, causing patients to refuse the treatm
Autor:
A Bustinza Txertudi, A De Basagoiti Gorordo, Z Baskaran Kaltzakorta, A Belaustegi Foronda, B San Jose Ruiz, B Baza Martinez, L. Serrano de Lucas, I Bilbao Meseguer, J Hernandez Goicoechea, MA Gil Lemus
Publikováno v:
European Journal of Hospital Pharmacy. 20:A40.2-A40
Background Glucarpidase (Voraxaze) is effective in the treatment of methotrexate (MTX)-induced renal dysfunction but many cases this can be handled with standard treatment. Purpose To describe the progress of a patient with MTX-induced renal failure
Autor:
M Castaño Lopez, A Belaustegi Foronda, A De Basagoiti Gorordo, S. Sautua Larreategi, I Bilbao Meseguer, J Hernandez Goicoechea, E Rodriguez España, B San Jose Ruiz, Z Baskaran Kaltzakorta, B Sordo Aisa
Publikováno v:
European Journal of Hospital Pharmacy. 20:A143.1-A143
Background Parenteral nutrition (PN) for neonates has to be infused by a central line, due to the high osmolarity resulting from the recommended requirements. The central catheter frequently needs to be removed, and therefore PN may have to be admini
Autor:
L Serrano Lucas De, I Bilbao Meseguer, A De Basagoiti Gorordo, Z Baskaran Kaltzakorta, A Bustinza Txertudi, A Belaustegui Foronda, J Hernandez Goicoechea, E Rodriguez España, B Baza Martinez, S. Sautua Larreategui
Publikováno v:
European Journal of Hospital Pharmacy. 20:A103.3-A103
Background Omalizumab’s labelled indication is the treatment of IgE-mediated asthma. It has been used in our hospital since 2008. In 2011 it became necessary to develop a protocol that clarified patient selection and criteria for withholding treatm